Inventor · disambiguated record
Jinzi Jason Wu
Also filed as: WU JINZI J · WU JINZI JASON
13 granted patents·27 pending applications·37 citations·filing 2004–2025
88Inventor score
Files withASCLETIS BIOSCIENCE CO LTD13GANNEX PHARMA CO LTD11ASCLETIS PHARMA CHINA CO LTD7NORTHRIDGE HEALTH GROUP HONG KONG CO LTD2AMBRILIA BIOPHARMA INC1
Top patents by PatentIndex Score
40 records- 0195US11541071B1Nucleoside derivatives and methods of use thereofASCLETIS BIOSCIENCE CO LTD·Filed 2022·Granted Jan 3, 2023·23 cites·20 claims
- 0294US12234236B1GLP-1R agonist and therapeutic method thereofASCLETIS PHARMA CHINA CO LTD·Filed 2024·Granted Feb 25, 2025·3 cites·25 claims
- 0394US11702406B1Triazine derivatives and methods of use thereofASCLETIS BIOSCIENCE CO LTD·Filed 2022·Granted Jul 18, 2023·4 cites·10 claims
- 0494US11292805B2Preparation method of a cyclic phosphonate compoundGANNEX PHARMA CO LTD·Filed 2021·Granted Apr 5, 2022·4 cites·14 claims
- 0593US11725019B2Preparation method of a cyclic phosphonate compoundGANNEX PHARMA CO LTD·Filed 2022·Granted Aug 15, 2023·2 cites·12 claims
- 0689US12291530B1GLP-1R agonist and therapeutic method thereofASCLETIS PHARMA CHINA CO LTD·Filed 2024·Granted May 6, 2025·1 cites·13 claims
- 0783US12084469B2Preparation method of a cyclic phosphonate compoundGANNEX PHARMA CO LTD·Filed 2023·Granted Sep 10, 2024·0 cites·16 claims
- 0883US2025346594A1GLP-1R Agonist and Therapeutic Method ThereofASCLETIS PHARMA CHINA CO LTD·Filed 2025·Application pending·0 cites
- 0983US2025346596A1GLP-1R Agonist and Therapeutic Method ThereofASCLETIS PHARMA CHINA CO LTD·Filed 2025·Application pending·0 cites
- 1083US2025346595A1GLP-1R Agonist and Therapeutic Method ThereofASCLETIS PHARMA CHINA CO LTD·Filed 2025·Application pending·0 cites
- 1179US12297193B2PTPN2/PTP1B degrader and therapeutic method thereofNORTHRIDGE HEALTH GROUP HONG KONG CO LTD·Filed 2024·Granted May 13, 2025·0 cites·8 claims
- 1276US2024189337A1Nucleoside derivatives and methods of use thereofASCLETIS BIOSCIENCE CO LTD·Filed 2023·Application pending·0 cites
- 1375US11865132B2Nucleoside derivatives and methods of use thereofASCLETIS BIOSCIENCE CO LTD·Filed 2022·Granted Jan 9, 2024·0 cites·11 claims
- 1474US12187704B2Triazine derivatives and methods of use thereofASCLETIS BIOSCIENCE CO LTD·Filed 2023·Granted Jan 7, 2025·0 cites·11 claims
- 1573US2025376470A1GLP-1R Agonist and Therapeutic Method ThereofASCLETIS PHARMA CHINA CO LTD·Filed 2025·Application pending·0 cites
- 1669US2023234921A1Inhibitors of cysteine proteases and methods of use thereofASCLETIS BIOSCIENCE CO LTD·Filed 2023·Application pending·0 cites
- 1768US2024294561A1Prodrugs of Thyroid Hormone Analogs, Methods of Making and Methods of Using ThereofGANNEX LLC·Filed 2024·Application pending·0 cites
- 1866US11760722B2Inhibitors of cysteine proteases and methods of use thereofASCLETIS BIOSCIENCE CO LTD·Filed 2022·Granted Sep 19, 2023·0 cites·4 claims
- 1965US2025011303A1Small molecule modulators of il-17a, methods of making and methods of using thereofASCLETIS BIOSCIENCE CO LTD·Filed 2024·Application pending·0 cites
- 2065US2024270756A1Integrase Inhibitor and Use ThereofASCLETIS BIOSCIENCE CO LTD·Filed 2024·Application pending·0 cites
- 2165US2024327428A1Inhibitors of human immunodeficiency virus replication, method of making and method of using thereofASCLETIS BIOSCIENCE CO LTD·Filed 2024·Application pending·0 cites
- 2260US2024025885A1Triazine derivatives and methods of use thereofASCLETIS BIOSCIENCE CO LTD·Filed 2022·Application pending·0 cites
- 2359US2025257062A1GLP-1R Agonist and Therapeutic Method ThereofASCLETIS PHARMA CHINA CO LTD·Filed 2025·Application pending·0 cites
- 2459US2024325417A1Combination therapy for treatment of liver diseasesGANNEX PHARMA CO LTD·Filed 2022·Application pending·0 cites
- 2559US2024293385A1Combination therapy for treatment of liver diseasesGANNEX PHARMA CO LTD·Filed 2022·Application pending·0 cites
- 2659US2023271949A1Glp-1r modulating compoundsASCLETIS BIOSCIENCE CO LTD·Filed 2022·Application pending·0 cites
- 2758US2025282766A1PTPN2/PTP1B Degrader and Therapeutic Method ThereofNORTHRIDGE HEALTH GROUP HONG KONG CO LTD·Filed 2025·Application pending·0 cites
- 2858US2008182777A1Regulation of cell migration and adhesionPANCHAL CHANDRA J·Filed 2007·Application pending·0 cites
- 2954US11752161B2Pharmaceutical compositions, method of making and method of using thereofGANNEX PHARMA CO LTD·Filed 2021·Granted Sep 12, 2023·0 cites·13 claims
- 3053US2005147601A1Regulation of cell migration and adhesionFiled 2004·Application pending·0 cites
- 3153US2012053139A1Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursorsWU JINZI JASON·Filed 2011·Application pending·0 cites
- 3253US2023364114A1Pharmaceutical compositions, method of making and method of using thereofGANNEX PHARMA CO LTD·Filed 2023·Application pending·0 cites
- 3352US2023357293A1Crystal of Thyroid Hormone B Receptor Agonist, Process for Preparing The Same and Use ThereofGANNEX PHARMA CO LTD·Filed 2020·Application pending·0 cites
- 3450US2024207290A1Cyclic phosphonate composition and preparation method thereofGANNEX PHARMA CO LTD·Filed 2022·Application pending·0 cites
- 3550US2006287316A1Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursorsAMBRILIA BIOPHARMA INC·Filed 2006·Application pending·0 cites
- 3648US11583502B2Pharmaceutical compositions comprising a thyroid hormone beta agonist, method of use and method making thereofGANNEX PHARMA CO LTD·Filed 2021·Granted Feb 21, 2023·0 cites·19 claims
- 3746US2005148514A1Method and composition for treatment of angiogenesisFiled 2004·Application pending·0 cites
- 3846US2025009726A1A pharmaceutical composition of fxr agonist and its preparation methodGANNEX PHARMA CO LTD·Filed 2021·Application pending·0 cites
- 3940US2021038681A1Pharmaceutical composition for treating viral hepatitis cASCLETIS BIOSCIENCE CO LTD·Filed 2018·Application pending·0 cites
- 4031US2008200393A1Method and Composition For Treating Angiogenesis and For Preventing Cancer Progression and Metastasis Comprising a Prostate Secretory Protein (Psp94) Family MemberAMBRILLIA BIOPHARMA INC·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →